Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bellerophon Therapeutics Inc BLPH

Healthcare Biotechnology
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company’s focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an... see more

Recent & Breaking News (GREY:BLPH)

Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

GlobeNewswire June 5, 2023

Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results

GlobeNewswire May 15, 2023

Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

GlobeNewswire May 11, 2023

Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results

GlobeNewswire March 31, 2023

Bellerophon Therapeutics Announces $5 Million Registered Direct Offering

GlobeNewswire March 6, 2023

Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung Disease

GlobeNewswire February 9, 2023

Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

GlobeNewswire January 18, 2023

Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciences

GlobeNewswire January 5, 2023

Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results

GlobeNewswire November 14, 2022

Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

GlobeNewswire September 27, 2022

Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 15, 2022

Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference

GlobeNewswire May 12, 2022

Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 11, 2022

Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results

GlobeNewswire March 31, 2022

Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

GlobeNewswire January 10, 2022

Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis

GlobeNewswire December 17, 2021

Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results

GlobeNewswire November 15, 2021

Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 7, 2021

Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results

GlobeNewswire August 5, 2021

Bellerophon to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 27, 2021